SK Plasma
SK Plasma Co., Ltd. is a South Korean company specializing in the production of plasma-derived products aimed at treating various medical conditions, including hypoalbuminemia, hemorrhagic shock, antithrombin deficiency, and tetanus. Established in 2015 and based in Seongnam-si, the company focuses on developing high-quality plasma derivatives that serve as essential medicines for conditions such as congenital immunodeficiency diseases and hemophilia. SK Plasma has gained a strong reputation in the export market, reflecting its commitment to enhancing human health and ensuring safety through its innovative products. As a subsidiary of SK Chemicals Co., Ltd., SK Plasma leverages its parent company's expertise while concentrating on its core competencies in plasma derivatives to provide effective solutions for healthcare professionals and patients alike.
1 past transactions
Curocell
Venture Round in 2022
Curocell Inc is a biotechnology company focused on medical and pharmaceutical research and development, specializing in innovative cancer therapies. The company utilizes its proprietary OVIS™ technology to enhance immune cells, enabling them to overcome immune suppression within tumor microenvironments. Curocell is particularly involved in the development of CAR-T treatments, which involve the genetic manipulation of human immune cells to improve their ability to identify and eliminate cancer cells. Through its advancements in immune cell enhancement, Curocell aims to contribute significantly to the field of cancer treatment, providing new hope for patients facing this challenging disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.